BioCryst Pharmaceuticals announced that it has signed a licensing agreement with the Irish subsidiary of Neopharmed Gentili regarding the rights to the hereditary angioedema treatment drug Navenibart in Europe.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Federal Reserve's Kashkari: US Treasury market continues to operate normally; rising yields do not affect monetary policy discussions
Minneapolis Federal Reserve President Neel Kashkari downplayed concerns over the rising yields of U.S. Treasury bonds, stating that the market is functioning well and the recent surge in yields is unlikely to affect monetary policy discussions.
New Zealand Dollar edges lower below 0.6000 after weaker Retail Sales data
Santos to buy 30% stake in Meridian CSG project for about US$85 million-US$90 million
Benz Mining raises A$150 million to accelerate Glenburgh drilling program
